Immunome Inc.

IMNMSEC EDGAR

Pharmaceutical Preparations(DE)CIK: 1472012

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue from Contract with Customer, Excluding Assessed Tax	$9.0M	$14.0M	$14.0M	—	—
Research and Development Expense	$129.5M	$23.1M	$23.3M	$14.1M	$7.5M
Operating Expenses	$314.8M	$123.5M	$36.9M	$25.2M	$12.3M
Operating Income (Loss)	-$305.8M	-$109.5M	-$36.9M	-$25.2M	-$12.3M
Other Nonoperating Income (Expense)	—	—	—	$493.0K	-$5.6M
Income Tax Expense (Benefit)	$0.00	$0.00	$0.00	$0.00	$0.00
Net Income (Loss) Attributable to Parent	-$293.0M	-$106.8M	-$36.9M	-$24.7M	-$17.8M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$240.2M	$148.5M	$24.0M	$57.9M	$44.5M
Assets, Current	$221.3M	$144.7M	$22.6M	$56.6M	$42.9M
Cash and Cash Equivalents, at Carrying Value	$143.4M	$98.7M	$20.3M	$49.2M	$39.8M
Liabilities	$59.1M	$28.7M	$7.4M	$9.7M	$3.2M
Liabilities, Current	$54.3M	$21.8M	$7.3M	$9.7M	$3.0M
Long-term Debt	—	—	—	—	—
Accounts Payable, Current	$14.2M	$3.3M	$2.4M	$3.1M	$1.2M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	-$110.8M	-$7.6M	-$28.7M	-$18.2M	-$12.1M
Net Cash Provided by (Used in) Investing Activities	-$85.1M	-$30.5M	-$248.0K	-$79.0K	-$586.0K
Net Cash Provided by (Used in) Financing Activities	$240.5M	$116.4M	$32.0K	$27.8M	$49.9M
Payments to Acquire Property, Plant, and Equipment	$7.2M	$831.0K	$248.0K	$79.0K	$586.0K

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)